Menu
← Oncology Approval Tracker
FDA DECISION ·
Breyanzi
lisocabtagene maraleucel · Juno Therapeutics (Bristol Myers Squibb)
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with relapsed or refractory follicular lymphoma after two or more prior systemic treatment lines.
LAMPGEN ANALYSIS
Why it matters
The accelerated approval extended CAR T therapy to a later-line follicular lymphoma population.
What research teams should watch
Collect prior systemic regimen and relapse dates and plan for long-term safety and response follow-up after infusion.
PRIMARY RECORDS